TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A, all the investigators of the Gruppo Oncologico del Nord Ovest

Open source

DOI
10.1186/s12885-017-3360-z
Published
2017 Jun 9
Container
BMC cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12885-017-3360-z,
  title = {TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.},
  author = {Cremolini C and Marmorino F and Loupakis F and Masi G and Antoniotti C and Salvatore L and Schirripa M and Boni L and Zagonel V and Lonardi S and Aprile G and Tamburini E and Ricci V and Ronzoni M and Pietrantonio F and Valsuani C and Tomasello G and Passardi A and Allegrini G and Di Donato S and Santini D and Falcone A and all the investigators of the Gruppo Oncologico del Nord Ovest},
  year = {2017},
  journal = {BMC cancer},
  doi = {10.1186/s12885-017-3360-z},
  url = {https://doi.org/10.1186/s12885-017-3360-z}
}

RIS

TY  - JOUR
TI  - TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
AU  - Cremolini C
AU  - Marmorino F
AU  - Loupakis F
AU  - Masi G
AU  - Antoniotti C
AU  - Salvatore L
AU  - Schirripa M
AU  - Boni L
AU  - Zagonel V
AU  - Lonardi S
AU  - Aprile G
AU  - Tamburini E
AU  - Ricci V
AU  - Ronzoni M
AU  - Pietrantonio F
AU  - Valsuani C
AU  - Tomasello G
AU  - Passardi A
AU  - Allegrini G
AU  - Di Donato S
AU  - Santini D
AU  - Falcone A
AU  - all the investigators of the Gruppo Oncologico del Nord Ovest
PY  - 2017
JO  - BMC cancer
DO  - 10.1186/s12885-017-3360-z
UR  - https://doi.org/10.1186/s12885-017-3360-z
ER  - 

APA

C, C., F, M., F, L., G, M., C, A., L, S., M, S., L, B., V, Z., S, L., G, A., E, T., V, R., M, R., F, P., C, V., G, T., A, P., G, A., S, D. D., D, S., A, F., & Ovest, A. T. I. O. T. G. O. D. N. (2017). TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.. BMC cancer. https://doi.org/10.1186/s12885-017-3360-z

Source records